Navigation Links
InterCure Names Scot Dube Vice President of Sales
Date:12/11/2007

Medical Device Industry Executive Brings More Than 30 Years Experience to

Personal Therapeutic Device Leader

NEW YORK, Dec. 11 /PRNewswire/ -- InterCure, Ltd. (Tel Aviv Stock Exchange: INCR) manufacturer of the RESPeRATE(R) hypertension treatment device, clinically-proven to significantly lower blood pressure, today announced the appointment of Scot Dube as Vice President of Sales. Dube brings more than 30 years of medical device and consumer product leadership to InterCure and will be a driving force as InterCure launches RESPeRATE into retail channels.

Prior to joining InterCure, Dube served as President of Microlife, USA, Inc., the U.S. subsidiary of Microlife Corporation, the Taiwanese-based international leader in the marketing and distribution of medical diagnostic products including blood pressure monitors, infrared and digital thermometers, peak flow meters and weight management devices. During his 10 years at Microlife, Dube successfully re-engineered the U.S. business from an OEM manufacturer to a leading direct-to-retail brand, driving growth through Wal-Mart, Costco, Walgreens, CVS and other key retailers. Under his leadership, Microlife's blood pressure monitoring business grew 15 share points in one year, garnering the number two share in the category. Prior to Microlife, Dube served as national sales and marketing manager for Florida Medical Industries, directing sales and marketing activities for both consumer diagnostic and therapeutic medical products. Dube also held sales and marketing positions of increasing responsibility at Becton Dickinson, Travenol Labs and Schering Laboratories.

"Scot's leadership within the consumer medical device industry -- and the hypertension market in particular -- coupled with his outstanding record of success in building sustained profitable growth within retail channels will be instrumental for RESPeRATE," said Erez Gavish, president and CEO of InterCure. "Scot will serve as a catalyst for expanding InterCure's retail presence and represents the last key piece of our world class sales and marketing organization. We are pleased to welcome Scot as a member of our executive management team."

"Having navigated the consumer healthcare market for three decades, I believe InterCure is uniquely positioned to tap the enormous growth occurring within the Personal Therapeutic Device category," said Scot Dube, new Vice- President of Sales, InterCure. "Retailers are actively seeking opportunities to drive incremental profit through new category evolution. I look forward to expanding InterCure's market position as both the innovator and leader in the important hypertension treatment market. Hypertension is reaching epidemic proportions in the United States and around the globe, and the need for effective treatments could not be greater. I look forward to leveraging my extensive sales and marketing management experience to launch and promote retail distribution, bringing the RESPeRATE device to store shelves across America."

About RESPeRATE

RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.

About InterCure, Ltd.

InterCure, a medical device company, publicly traded on the Tel Aviv Stock Exchange (TASE: INCR) has become a leader in the growing Personal Therapeutic Device category. Its broadly patented "device-guided breathing" technology platform enables a systematic reduction in sympathetic outflow of the autonomic nervous system. InterCure is successfully selling the world's first hypertension treatment device, RESPeRATE(R), with more than 75,000 units sold. With multiple published clinical studies, regulatory clearance in most key international markets (including FDA over-the-counter ("OTC") clearance in the U.S., the European CE mark and the Chinese SDA among others) and a renowned scientific advisory board, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension. (http://www.intercure.com)

Forward-Looking Statements

This news release may contain forward-looking statements that are based on the Company's current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward- looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

Contacts:

Lisa Mokaba Brian Packard

Schwartz Communications InterCure, Inc.

781-684-0770 646-652-5800 x.7134

intercure@schwartz-pr.com bpackard@intercure.com


'/>"/>
SOURCE InterCure, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. InterCure and High Tech Health Announce RESPeRATE Launch into Pharmacy Market in Australia
2. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
3. Mediware Names Thomas K. Mann Chief Executive Officer
4. Cleveland-based Health Care Tech Company Within3 Names New CEO
5. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
6. Patient Safety Authority Board of Directors Names Infection Advisory Panel
7. Hooper Holmes Names Chris Behling President of Health & Wellness Division
8. MDMA Names New Director of Federal Affairs
9. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
10. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
11. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
(Date:4/28/2017)... ... April 28, 2017 , ... NuevaCare, a leading home ... as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to its ... bookmark and read organized content on topics such as home care (generally) as well ...
(Date:4/27/2017)... ... April 27, 2017 , ... Today, ... based in Denver, Colorado, announced an agreement to create the Jane and Leonard ... of the Jane and Leonard Korman Family Foundation. The collaboration leverages the strengths ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... , April 19, 2017 Global ... This report on the prostate cancer therapeutics market ... global market. Increasing prevalence of prostate cancer, launch ... in the development of new drugs & therapeutic ... cancer drug due to lesser side effects are ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
Breaking Medicine Technology: